Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
BörsenkürzelAXGN
Name des UnternehmensAxoGen Inc
IPO-datumDec 17, 1986
CEOMr. Michael Donald (Mike) Dale
Anzahl der mitarbeiter451
WertpapierartOrdinary Share
GeschäftsjahresendeDec 17
Addresse13631 Progress Blvd.
StadtALACHUA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl32615
Telefon13864626817
Websitehttps://www.axogeninc.com/
BörsenkürzelAXGN
IPO-datumDec 17, 1986
CEOMr. Michael Donald (Mike) Dale
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten